Home > ASQ Washington, DC &... > Events > Attend an Event > Biomed/Biotech SIG:...


Biomed/Biotech SIG: Leukemia - What We Should Know
Where
9366 Gaither Rd. 1st Fl Music Room, Gaithersburg, MD 20877
When
Jul 12, 2018
6:00 pm - 8:45 pm
(GMT -5:00) EST
“A Commotion
in the Blood
– What We Should Know About
Leukemia”
To be
presented by
Ashley Ward,
MD
Clinical Team
Lead
Division of
Hematology Products (DHP)
Office of Hematology and
Oncology Products (OHOP)
Oncology Center for
Excellence (OCE), US FDA
Thursday, July
12, 2018
Venue: 9366 Gaither Rd.
“1st Floor Music Room”, Gaithersburg, MD
20877 (CCACC)
6:00
– 6:20 PM – Networking;
Pizza/drink
6:20
– 8:50 PM –
Program
8:50
– 9:00 PM – Door-prizes drawing;
Networking
Online Registration
site: http://www.asq509.org/ht/d/DoSurvey/i/35817
Open
to Public –
$5: non-ASQ members
to cover pizza/drink
cost;
Free: ASQ members,
current job-seekers, CCACC
volunteers/employees/members, veterans, senior
citizens, past speakers, US PHS Commissioned
Corp officers, teachers, students, interns,
residents, postdocs, FDA Commissioner’s
Fellows, MJ-DC members, NTUAADC members, CAPA
members, NTMUADC members, CKUAADC members,
NTHUAADC members, NJTUAADC members, FAPAC
members, CBA members, AAGEN members, NCARSQA
members, OCA-DC members, AAMB members, ACAP
members, DC Leaders Club members, BioTrain
volunteers, and all Tai-Chi classes students in
the Metropolitan Washington
DC.
Registration
Deadline: Please register by
Thursday noon, July 12,
2018.
Question: Please
contact Dr. C.J. George Chang, Chair of
Biomed/Biotech SIG, ASQ509;
gchang2008@yahoo.com or 240-793-8425
(cell).
Driving
directions: By Cars: From I-270 (N
or S bound): Take Exit 8 onto Shady Grove Dr.
Drive toward east and turn left onto Gaither
Rd. The building is on your left after passing
a stop sign. By Metro rail: Exit at the Red
Line Shady Grove
Station.
Summary
Leukemia is a
collection of cancers that begin in blood cells
in the bone marrow. While relatively rare in
adults compared to other types of cancer (e.g.,
lung, breast), it is the most common cancer in
children and is the cause of over 350,000
global deaths per year. Leukemia was
universally fatal with no available treatments
until the late 1940s when Dr. Sidney Farber, a
pathologist at Harvard Medical School,
administered the first chemotherapy to children
with leukemia and got them into a temporary
remission. Since that time, regular advances in
leukemia therapy have led to long-term survival
rates exceeding 50% in adults and 90% in
children.
In this presentation, Dr. Ward will
explain the different types of leukemia (acute
versus chronic, myeloid versus lymphoid) and
what that means with respect to treatment and
long-term outcomes. She will describe how the
diagnosis of leukemia is made, and what the
experience of leukemia treatment is like for
the patient, their family members, and the
physician. Finally, Dr. Ward will summarize
what is known about the epidemiology of
leukemia (who gets leukemia and why), as well
as available treatment options, from widely
used and very effective chemotherapy agents to
new and targeted scientifically advanced
therapies that have in some cases dramatically
extended life expectancy.
Speaker
Dr. Ashley Ward is
pediatric oncologist and clinical team leader
in the Office of Oncology and Hematology
Products at the Oncology Center for Excellence
(OCE), U.S. Food and Drug Administration. Her
work focuses on the evaluation of
investigational new drug applications (INDs)
and marketing applications (NDAs and BLAs) for
drugs for the treatment of cancer, and she
specializes in acute leukemia, melanoma, and
sarcoma.
Previously, Dr. Ward was an assistant
professor at the University of California, San
Francisco (UCSF), where she cared for patients,
taught medical students, residents, and
fellows, and studied the role of individual Ras
effector pathways in the development of myeloid
malignancies in the laboratory. She also spent
several years as a medical director in the
early clinical development group at Genentech,
where she led the development teams for several
small molecules and antibody-drug conjugates
through early phase testing for hematologic
malignancies and breast
cancer.
Dr. Ward received her Bachelor’s
degree in Biology from Swarthmore College and
her medical degree from Washington University
School of Medicine. She completed her residency
and chief residency at St. Louis Children’s
Hospital, and her fellowship in pediatric
hematology and oncology at the University of
California, San Francisco, CA.
This
event is cosponsored by Chinese Culture and
Community Service Center, Inc. (CCACC,
www.ccacc-dc.org), NTU Alumni Association DC
Chapter (www.ntuaadc.org), and Chinese American
Professionals Association of Metropolitan
Washington, DC
(www.capadc.org).